| 1 Gao S, Wang YJ, Xu AD, et al. Chinese ischemic stroke subclassification[J]. Front Neurol, 2011, 2:6.2 Kannel WB, Wolf PA, Verter J, et al. Epidemiologic assessment of the role of blood pressure in stroke. The Framingham study[J]. JAMA, 1970, 214:301-310.3 PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among individuals with previous stroke or transient ischaemic attack[J]. Lancet, 2001, 358:1033-1041.4 Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension:The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J]. J Hypertens, 2007, 25:1105-1187.5 Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial[J]. J Am Soc Nephrol, 2005, 16:2170-2179.6 Messerli FH, Mancia G, Conti CR, et al. Dogma disputed:can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?[J]. Ann Intern Med, 2006, 144:884-893.7 Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study[J]. J Hypertens, 2009, 27:1360-1369.8 Okin PM, Hille DA, Kjeldsen SE, et al. Impact of lower achieved blood pressure on outcomes in hypertensive patients[J]. J Hypertens, 2012, 30:802-810.9 Pepine CJ, Handberg EM, CooperDeHoff RM, et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST):a randomized controlled trial[J]. JAMA, 2003, 290:2805-2816.10 Hansson L, Zanchetti A, Carruthers SG, et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:principal results of the Hypertension Optimal Treatment (HOT) randomised trial[J]. Lancet, 1998, 351:1755-1762.11 Mancia G, Schumacher H, Redon J, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET)[J]. Circulation, 2011, 124:1727-1736.12 Barzilay JI, Howard AG, Evans GW, et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes:the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial[J]. Diabetes Care, 2012, 35:1401-1405.13 Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose:observations from traditional and Bayesian random-effects meta-analyses of randomized trials[J]. Circulation, 2011, 123:2799-2810. |
